Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations

Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations

October 03, 2007

    PITTSBURGH, Oct. 3 /Xinhua-PRNewswire/ -- Mylan Inc.
(NYSE: MYL) today announced the appointment of Rajiv Malik
as Executive Vice President in charge of Global Technical
Operations.  Mr. Malik has served in a similar capacity for
Mylan since the Company acquired a controlling stake in
Matrix Laboratories Limited (Matrix), where he is Chief
Executive Officer, in January 2007.  

    As Head of Global Technical Operations, Mr. Malik will
oversee the Company's global research and development
(R&D) centers and manufacturing and distribution units,
with responsibility for enhancing and rationalizing Mylan's
global supply chain and expanded product pipeline, as well
as leveraging Matrix, one of the world's largest suppliers
of active pharmaceutical ingredients, across the enlarged
company.  

    Mr. Malik has worked more than 24 years in the global
generic pharmaceutical industry.  In addition to his role
at Mylan, Mr. Malik currently serves as Managing Director
and Chief Executive Officer of Matrix.   Prior to joining
Matrix in 2005, he was Head of Global Development and
Regulatory at Sandoz.  He started his career in R&D at
Ranbaxy Laboratories, rising to Head of Generics R&D. 

    Mylan's Vice Chairman and CEO Robert J. Coury
commented, "Rajiv has been an invaluable addition to
the Mylan management team since joining us in January. 
Since the close of the Matrix transaction, he has truly
proven his capabilities and has been instrumental in the
successful integration of Matrix.  Rajiv has built an
outstanding operational infrastructure that will allow us
to capitalize on the efficiencies, synergies and sourcing
opportunities we see from bringing together all three
companies." 

    Mr. Malik earned his master's degree in pharmaceutical
technology from Punjab University and has more than 60
process patents to his credit. 

    Mylan Inc. is one of the world's leading quality
generic and specialty pharmaceutical companies. The Company
offers one of the industry's broadest and highest quality
product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90
countries.  Through its controlling interest in Matrix
Laboratories Limited, Mylan has direct access to one of the
largest active pharmaceutical ingredient (API) manufacturers
in the world.   Dey L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and
diversified opportunities in the respiratory and allergy
therapeutic areas.  

    For more information about Mylan, please visit
http://www.mylan.com .


    For more information, please contact:

     Kris King, 
     Mylan Inc.
     Tel:  [phone]